{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T21:10:16Z","timestamp":1788988216795,"version":"build-2803163510"},"reference-count":41,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["2020\/R-Single\/027"],"award-info":[{"award-number":["2020\/R-Single\/027"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007366","name":"Italian Multiple Sclerosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007366","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.neurot.2026.e00940","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T12:53:15Z","timestamp":1780923195000},"page":"e00940","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Short-term effects of ocrelizumab on cortical pathology in patients with multiple sclerosis"],"prefix":"10.1016","volume":"23","author":[{"given":"N.","family":"Cavalli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Boffa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Cipriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.D.","family":"Boccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Al Qudsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Baldisseri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Leveraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Nasone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Magon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Cellerino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Inglese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Lapucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.neurot.2026.e00940_bib1","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1056\/NEJMra1401483","article-title":"Multiple sclerosis","volume":"378","author":"Reich","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00940_bib2","first-page":"229","article-title":"The histology of disseminated sclerosis","volume":"17","author":"Dawson","year":"1916","journal-title":"Edinb Med J"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00940_bib3","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1001\/archneur.64.1.76","article-title":"Lack of correlation between cortical demyelination and white matter pathologic changes in multiple sclerosis","volume":"64","author":"B\u00f6","year":"2007","journal-title":"Arch Neurol"},{"issue":"9","key":"10.1016\/j.neurot.2026.e00940_bib4","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1474-4422(08)70191-1","article-title":"Grey matter pathology in multiple sclerosis","volume":"7","author":"Geurts","year":"2008","journal-title":"Lancet Neurol"},{"issue":"8","key":"10.1016\/j.neurot.2026.e00940_bib5","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/nrneurol.2010.93","article-title":"Cortical lesions in multiple sclerosis","volume":"6","author":"Calabrese","year":"2010","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00940_bib6","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s41747-020-00186-x","article-title":"Ultra-high-field 7-T MRI in multiple sclerosis and other demyelinating diseases: from pathology to clinical practice","volume":"4","author":"Bruschi","year":"2020","journal-title":"Eur Radiol Exp"},{"key":"10.1016\/j.neurot.2026.e00940_bib7","first-page":"217","article-title":"The neuropathology of multiple sclerosis","volume":"vol. 9","author":"Lumsden","year":"1970"},{"issue":"10","key":"10.1016\/j.neurot.2026.e00940_bib8","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1001\/archneur.64.10.1416","article-title":"Detection of cortical inflammatory lesions by double inversion recovery magnetic resonance imaging in patients with multiple sclerosis","volume":"64","author":"Calabrese","year":"2007","journal-title":"Arch Neurol"},{"issue":"Pt 10","key":"10.1016\/j.neurot.2026.e00940_bib9","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1093\/brain\/aws246","article-title":"Cortical lesion load associates with progression of disability in multiple sclerosis","volume":"135","author":"Calabrese","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.neurot.2026.e00940_bib10","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol"},{"issue":"22","key":"10.1016\/j.neurot.2026.e00940_bib11","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1212\/WNL.0b013e3181ff96f6","article-title":"Intracortical lesions: relevance for new MRI diagnostic criteria for multiple sclerosis","volume":"75","author":"Filippi","year":"2010","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00940_bib12","doi-asserted-by":"crossref","first-page":"e308","DOI":"10.1212\/WNL.0000000000201465","article-title":"Differentiating multiple sclerosis from AQP4-Neuromyelitis optica spectrum disorder and MOG-antibody disease with imaging","volume":"100","author":"Cortese","year":"2023","journal-title":"Neurology"},{"issue":"16","key":"10.1016\/j.neurot.2026.e00940_bib13","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1212\/WNL.0b013e31826e9a96","article-title":"No MRI evidence of cortical lesions in neuromyelitis optica","volume":"79","author":"Calabrese","year":"2012","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.neurot.2026.e00940_bib14","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1007\/s00415-012-6571-x","article-title":"Patients with migraine do not have MRI-visible cortical lesions","volume":"259","author":"Absinta","year":"2012","journal-title":"J Neurol"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00940_bib15","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.934","article-title":"Clinical significance of cortical lesions in patients with multiple sclerosis: a neuropsychological and neuroimaging study","volume":"8","author":"Matsushita","year":"2018","journal-title":"Brain Behav"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00940_bib16","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3174\/ajnr.A2340","article-title":"Identification and clinical impact of multiple sclerosis cortical lesions as assessed by routine 3T MR imaging","volume":"32","author":"Mike","year":"2011","journal-title":"AJNR Am J Neuroradiol"},{"issue":"11","key":"10.1016\/j.neurot.2026.e00940_bib17","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.neurot.2026.e00940_bib18","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1001\/jamaneurol.2015.1241","article-title":"Association of cortical lesion burden on 7-T magnetic resonance imaging with cognition and disability in multiple sclerosis","volume":"72","author":"Harrison","year":"2015","journal-title":"JAMA Neurol"},{"issue":"9","key":"10.1016\/j.neurot.2026.e00940_bib19","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1177\/1352458511404916","article-title":"Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability","volume":"17","author":"Roosendaal","year":"2011","journal-title":"Mult Scler"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00940_bib20","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/ana.21423","article-title":"Gray matter atrophy is related to long-term disability in multiple sclerosis","volume":"64","author":"Fisniku","year":"2008","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00940_bib21","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s13311-016-0479-6","article-title":"Imaging as an outcome measure in multiple sclerosis","volume":"14","author":"Ontaneda","year":"2017","journal-title":"Neurotherapeutics"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00940_bib22","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon Beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00940_bib23","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1007\/s13311-021-01104-8","article-title":"Predictors of Ocrelizumab effectiveness in patients with multiple sclerosis","volume":"18","author":"Cellerino","year":"2021","journal-title":"Neurotherapeutics"},{"issue":"13","key":"10.1016\/j.neurot.2026.e00940_bib24","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1177\/13524585221104014","article-title":"Two years\u2019 effect of dimethyl fumarate on focal and diffuse gray matter pathology in multiple sclerosis","volume":"28","author":"Marastoni","year":"2022","journal-title":"Mult Scler"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00940_bib25","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1177\/1352458510394702","article-title":"Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple sclerosis","volume":"18","author":"Calabrese","year":"2012","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurot.2026.e00940_bib26","doi-asserted-by":"crossref","DOI":"10.1177\/1756286418805713","article-title":"NEDA-3 status including cortical lesions in the comparative evaluation of natalizumab versus fingolimod efficacy in multiple sclerosis","volume":"11","author":"Puthenparampil","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.neurot.2026.e00940_bib27","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s12883-014-0171-6","article-title":"The brief International Cognitive Assessment for Multiple Sclerosis (BICAMS): normative values with gender, age and education corrections in the Italian population","volume":"14","author":"Goretti","year":"2014","journal-title":"BMC Neurol"},{"issue":"11","key":"10.1016\/j.neurot.2026.e00940_bib28","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1001\/jamaneurol.2023.3331","article-title":"Harmonizing definitions for progression independent of relapse activity in multiple sclerosis: a systematic review","volume":"80","author":"M\u00fcller","year":"2023","journal-title":"JAMA Neurol"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00940_bib29","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.221425","article-title":"Multicenter evaluation of AI-generated DIR and PSIR for cortical and juxtacortical multiple sclerosis lesion detection","volume":"307","author":"Bouman","year":"2023","journal-title":"Radiology"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00940_bib30","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1177\/13524585211029860","article-title":"Artificial double inversion recovery images for (juxta)cortical lesion visualization in multiple sclerosis","volume":"28","author":"Bouman","year":"2022","journal-title":"Mult Scler"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00940_bib31","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1212\/WNL.0b013e31820a0cc4","article-title":"Consensus recommendations for MS cortical lesion scoring using double inversion recovery MRI","volume":"76","author":"Geurts","year":"2011","journal-title":"Neurology"},{"issue":"14","key":"10.1016\/j.neurot.2026.e00940_bib32","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1212\/WNL.0b013e3181f5d4da","article-title":"Imaging distribution and frequency of cortical lesions in patients with multiple sclerosis","volume":"75","author":"Calabrese","year":"2010","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00940_bib33","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1007\/s00415-023-12179-y","article-title":"Ocrelizumab reduces cortical and deep grey matter loss compared to the S1P-receptor modulator in multiple sclerosis","volume":"271","author":"Bajrami","year":"2024","journal-title":"J Neurol"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00940_bib34","doi-asserted-by":"crossref","first-page":"fcae158","DOI":"10.1093\/braincomms\/fcae158","article-title":"Contribution of new and chronic cortical lesions to disability accrual in multiple sclerosis","volume":"6","author":"Beck","year":"2024","journal-title":"Brain Commun"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00940_bib35","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1148\/radiol.2019181719","article-title":"Longitudinal characterization of cortical lesion development and evolution in multiple sclerosis with 7.0-T MRI","volume":"291","author":"Treaba","year":"2019","journal-title":"Radiology"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00940_bib36","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1177\/13524585211005657","article-title":"Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy","volume":"28","author":"Signoriello","year":"2022","journal-title":"Mult Scler"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00940_bib37","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/jnen\/64.2.147","article-title":"The pathology of multiple sclerosis is location-dependent: no significant complement activation is detected in purely cortical lesions","volume":"64","author":"Brink","year":"2005","journal-title":"J Neuropathol Exp Neurol"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00940_bib38","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/nen.0b013e318040b2de","article-title":"The blood-brain barrier in cortical multiple sclerosis lesions","volume":"66","author":"van Horssen","year":"2007","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.neurot.2026.e00940_bib39","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/nyas.12841","article-title":"Pathological differences between white and grey matter multiple sclerosis lesions","volume":"1351","author":"Prins","year":"2015","journal-title":"Ann N Y Acad Sci"},{"issue":"13","key":"10.1016\/j.neurot.2026.e00940_bib40","doi-asserted-by":"crossref","first-page":"e1854","DOI":"10.1212\/WNL.0000000000010376","article-title":"Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension","volume":"95","author":"Hauser","year":"2020","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00940_bib41","first-page":"620","article-title":"Leptomeningeal contrast enhancement is related to focal cortical thinning in relapsing-remitting multiple sclerosis: a cross-sectional MRI study","volume":"40","author":"Bergsland","year":"2019","journal-title":"AJNR Am J Neuroradiol"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926001108?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926001108?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:36:14Z","timestamp":1788986174000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747926001108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1878747926001108"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e00940","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Short-term effects of ocrelizumab on cortical pathology in patients with multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e00940","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00940"}}